The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

Are you planning on having an IUD placed? If you are already planning to get an IUD, this study gives the chance to receive extra pain medication during insertion. Everyone will receive standard pain medication, and 2/3 of volunteers will receive extra. We are looking to see if giving ketorolac pills 1-hour vs 2-hours before an IUD decreases pain levels. We would need 3 hours of in-person clinic time from volunteers. Compensation provided.

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

Are you in perimenopause? Are you interested in lifting weights and taking creatine supplements? Do you want to learn more about your body and brain? If so, you may be able to participate in a research study to understand the impact of resistance training and creatine on muscle quality and cognition in perimenopause!

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

Have you been diagnosed hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer, and have not received any systemic anti-cancer treatment for the disease. The study will explore the effects of the study drug PF-07220060 plus letrozole and if it is more effective compared to currently approved drugs (palbociclib, abemaciclib, or ribociclib) in combination with letrozole. This study is different from your regular medical care. The purpose of your regular medical care is to manage or improve your health, but the purpose of research is to gather information to advance science and medicine and does not replace your regular medical care.

This study's findings will contribute to a broader understanding of how goal framing and self-regulatory tools can promote sustained engagement in health-related behaviors. Maintaining good health is essential for everyone. By participating in this study, you will help demonstrate the role of motivation in encouraging individuals to take action toward improving their health through health-related behaviors.

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel

If you have protein in the urine and African descent, Hispanic or American Indian you might have a gene call APOL1 contributing kidney disease. This study will test if you have change in the gene. If you do have that change you can participate in this study .

The main purpose of this study is to test the safety of a gene therapy. Scientists have created a gene in the laboratory that could be transferred to the cells in the body. This gene carries information to tell the cells how to make an antibody (protein). The antibody (protein) is very similar to an antibody (protein) called blinatumomab. Blinatumomab is an FDA-approved treatment for relapsed or refractory B-cell ALL. This gene therapy is not approved by the FDA, therefore is it experimental. This study tests different doses of the gene therapy to see which dose is safer in people since it has not been tested in people yet.